Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 6, 2015, Pages 711-717

  Li, Hong Xia ^a   Gao, Jing Miao ^a   Liang, Jia Qi ^a   Xi, Jun Min ^a   Fu, Meng ^a   Wu, Yong Jie ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Cell proliferation; Metformin; Prostate cancer; Synergism; Vitamin D3

Indexed keywords

COLECALCIFEROL; HOE 33342; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN S6; GROWTH INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADJUVANT THERAPY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALE; METHYL THIAZOLYL TETRAZOLIUM ASSAY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; CELL CYCLE; CELL LINE, TUMOR; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GROWTH INHIBITORS; HUMANS; MALE; METFORMIN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930327925     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12409     Document Type: Article

References (26)

1. Gulley J, Figg WD, Dahut WL. Treatment options for androgen-independent prostate cancer. Clin. Adv. Hematol. Oncol. 2003; 1: 49-57.
2. Aragon-Ching JB, Dahut WL. Chemotherapy in Androgen-Independent Prostate Cancer (AIPC):What's next after taxane progression? Cancer Ther. 2007; 5: 151-60.
3. Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F. Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int. J. Oncol. 2012; 40: 1313-20.
4. UKPDS G. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
5. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-86.
6. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. (Phila). 2008; 15: 369-75.
7. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. J. Geriatr. Oncol. 2014; 5: 281-9.
8. Meija L, Šitova A, Zeltīte R, et al. Vitamin D intake and deficiency in men at risk of prostate cancer. Eur. Urol. Suppl. 2010; 9: 536.
9. Zhao XY, Peehl DM, Navone NM, Feldman D. 1a, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000; 141: 2548-56.
10. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1a, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1995; 1: 997-1003.
11. Schwartz GG, Wang M-H, Zhang M, et al. 1a, 25-dihydroxyvitamin D3 (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 727-32.
12. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiol. 2013; 37: 207-18.
13. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin antineoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 2008; 19: 246-50.
14. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66: 10269-73.
15. Kelsey L, Katoch P, Ray A, et al. Vitamin D3 regulates the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells. PLoS One 2014; 9: e106437.
16. Di Bella G, Mascia F, Ricchi A, Colori B. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: A preliminary report. Neuro. Endocrinol. Lett. 2013; 34: 660-8.
17. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002; 143: 2508-14.
18. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog. 2010; 49: 662-71.
19. Colquhoun AJ, Venier NA, Vandersluis AD, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012; 15: 346-52.
20. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother. Pharmacol. 1989; 24: 181-6.
21. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008; 9: 47-59.
22. Roznovanu SL, Amălinci C, Rădulescu D. Molecular mechanisms in hormone-resistant prostate cancer. Rev. Med. Chir. Soc. Med. Nat. Iasi 2005; 109: 577-83.
23. Zou H, Lai Y, Zhao X, et al. Regulation of mammalian target of rapamycin complex 1 by Bcl-2 and Bcl-XL proteins. J. Biol. Chem. 2013; 288: 28824-30.
24. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008; 21: 1156-67.
25. Dang CV. MYC on the Path to Cancer. Cell 2012; 149: 22-35.
26. Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013; 34: 2823-32.